Hematologic Oncology

Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.

Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.

The FDA has granted accelerated approval to subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma after 2 prior therapies.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Frontline dasatinib was linked to frequent T315I mutations at relapse in Ph+ ALL, while ponatinib showed fewer resistance mutations and favorable outcomes.

Tafasitamab plus lenalidomide and rituximab has been approved by the European Commission in relapsed/refractory follicular lymphoma.

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib as a targeted therapy for relapsed/refractory, NPM1-mutant AML.

Anand Patel, MD, shares primary efficacy results from a phase 2 study evaluating a TKI plus inotuzumab ozogamicin–based therapy in newly diagnosed Ph-positive ALL.

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

TERN-701 yielded a high response rate with deep molecular responses in patients with heavily pretreated chronic phase chronic myeloid leukemia.

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

The FDA has accepted and granted priority review to the sBLA for nivolumab plus AVD in untreated adult and pediatric classical Hodgkin lymphoma.

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Long-term follow-up data from the AGAVE-201 trial showed that safety and survival outcomes with axatilimab were maintained in patients with chronic GVHD.

The FDA has approved the HSCT therapy for patients 6 years or older with SAA following reduced-intensity conditioning who do not have a compatible donor.

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.